EDIT Editas Medicine, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 5, 2026
$2,62
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$1,6752-Wochen-Tief
$4,5452-Wochen-Hoch
Marktkapitalisierung (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
Umsatz (TTM)
$47M
Ihre Abzeichen
52W-Spanne
$2–$5
Analystenbewertung
BUY
Kursziel
$6
P/E
-4.0
ROE
-118.8%
Nettogewinnmarge
-157.3%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
EDIT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$2.62
Marktkapitalisierung (MRQ)
$256M
P/E (TTM)
-4.0
EPS (TTM)
$-0.66
Umsatz (TTM)
$47M
ROE (TTM)
-118.8%
Verschuldungsgrad (MRQ)
0.5
52W-Spanne
$2–$5
EDIT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über Editas Medicine, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Editas Medicine, ehemals Gengine, Inc., ist ein US-amerikanisches Biotechnologieunternehmen, das an Therapien auf der Grundlage der CRISPR/Cas-Methode forscht. Editas hat seinen Sitz in Cambridge, Massachusetts, und verfügt über Forschungseinrichtungen in Boulder, Colorado.
## Geschichte
Editas wurde ursprünglich unter dem Namen Gengine, Inc. im September 2013 von Feng Zhang vom Broad Institute, Jennifer Doudna von der University of California, Berkeley, und George Church, David Liu und J. Keith Joung von der Harvard University gegründet und von Risikokapitalgebern finanziert; der Name wurde zwei Monate später in den aktuellen Namen Editas Medicine geändert. Doudna verließ das Unternehmen im Juni 2014 wegen rechtlicher Differenzen über das geistige Eigentum an Cas9.
Im August 2015 erhielt das Unternehmen in einer Finanzierungsrunde 120 Millionen US-Dollar von Bill Gates und weiteren Investoren. Am 2. Februar 2016 ging das Unternehmen an die Börse, wobei es 94 Millionen US-Dollar einnahm.
Im März 2020 hat Editas in Zusammenarbeit mit Allergan als erstes Unternehmen versucht, mit dem CRISPR-Verfahren DNA im Körper eines Menschen (in vivo) zu verändern. Im Rahmen der klinischen Studie erhielt ein Patient, der aufgrund der Leberschen kongenitalen Amaurose fast blind war, eine intravitreale Injektion mit einem harmlosen Virus, das die CRISPR-Anweisungen zur Genmanipulation trug. Auch an Therapien zur Heilung von Sichelzellkrankheit forscht das Unternehmen. Im Januar 2021 teilte das Unternehmen mit, dass es von der Food and Drug Administration die Genehmigung für Klinische Studien der Phase 1 erhalten habe.
== Einzelnachweise ==
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealthcare
BrancheBiotechnology
Mitarbeiter87
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$41M2016-12-31 → 2025-12-31
EPS$-1.802019-12-31 → 2025-12-31
Freier Cashflow$-166M2016-12-31 → 2025-12-31
Nettogewinnmarge-157.3%2018-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | EDIT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -4.05-Jahres-Durchschnitt ≈-3.7 | ≈-3.7 | · | · | |
| P/S (TTM) | 5.55-Jahres-Durchschnitt ≈24.2 | ≈24.2 | 11.6 | Unterbewertet | |
| K/B (MRQ) | 2.45-Jahres-Durchschnitt ≈3.1 | ≈3.1 | 2.2 | Überbewertet | |
| EV / EBITDA | -1.1 | · | · | · | |
| Kurs / FCF (TTM) | -2.15-Jahres-Durchschnitt ≈-4.3 | ≈-4.3 | · | · | |
| Kurs / Cashflow (TTM) | -2.15-Jahres-Durchschnitt ≈-4.5 | ≈-4.5 | · | · | |
| EV / Umsatz (TTM) | 2.1 | · | · | · | |
| EV / FCF (TTM) | -0.8 | · | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 9.45-Jahres-Durchschnitt ≈3.1 | ≈3.1 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | EDIT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -161.4%5-Jahres-Durchschnitt ≈-658.2% | ≈-658.2% | -334.4% | Spitzenklasse | |
| EBITDA Margin (EBITDA-Marge) | -394.9%5-Jahres-Durchschnitt ≈-658.2% | ≈-658.2% | -334.4% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | -157.3%5-Jahres-Durchschnitt ≈-639.3% | ≈-639.3% | -300.0% | Spitzenklasse | |
| ROA (TTM) | -33.0%5-Jahres-Durchschnitt ≈-43.0% | ≈-43.0% | -47.0% | Schwach | |
| ROE (TTM) | -118.8%5-Jahres-Durchschnitt ≈-195.1% | ≈-195.1% | -63.2% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | EDIT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.5 | · | 0.0 | Hohe Verschuldung | |
| Liquiditätsgrad (MRQ) | 3.25-Jahres-Durchschnitt ≈5.9 | ≈5.9 | 5.6 | Geringe Liquidität | |
| Quick Ratio (MRQ) | 3.15-Jahres-Durchschnitt ≈5.8 | ≈5.8 | 4.2 | Geringe Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.5 | · | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | EDIT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 25.4%5-Jahres-Durchschnitt ≈33.7% | ≈33.7% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 27.2%5-Jahres-Durchschnitt ≈10.1% | ≈10.1% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | -14.9% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | EDIT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.25-Jahres-Durchschnitt ≈0.1 | ≈0.1 | 0.1 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 2.65-Jahres-Durchschnitt ≈6.1 | ≈6.1 | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$465.7K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
2.8%
Nächster Bericht
Nov 09, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 10, 2026 | $-0.15 | $-0.28 | 45.5% |
| 31. März 2026 | Mai 11, 2026 | $-0.26 | $-0.27 | 3.3% |
| 31. Dezember 2025 | $-0.06 | $-0.26 | 77.2% | |
| 30. September 2025 | $-0.28 | $-0.30 | 7.3% | |
| 30. Juni 2025 | $-0.63 | $-0.38 | -63.8% | |
| 31. März 2025 | $-0.92 | $-0.60 | -53.1% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| R&D Expense | $90M | $199M | $178M | $175M | $143M | $158M | $97M | $91M | $83M | $57M | |
| SG&A Expense | $50M | $72M | $70M | $71M | $76M | $68M | $65M | $55M | $51M | $46M | |
| Operating Expenses | $201M | $283M | $247M | $246M | $219M | $226M | $161M | $146M | $134M | $103M | |
| Operating Income | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M | |
| Other Non-op | $-2M | $-3.0K | $-2M | $0 | $37.0K | $16M | $-137.0K | $328.0K | $587.0K | $-57.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | |
| Net Income | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · | |
| Shares (Basic) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| Shares (Diluted) | 88,745,908 | 82,338,220 | 75,965,633 | 68,664,822 | 67,619,388 | 58,609,389 | 49,983,329 | · | · | · | |
| EBITDA | $-160M | $-251M | $-169M | $-226M | $-193M | $-135M | $-141M | $-114M | $-120M | $-97M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $147M | $132M | $124M | $142M | $204M | $140M | $238M | $135M | $147M | $185M | |
| Short-term Investments | $0 | $138M | $199M | $203M | $296M | $262M | $219M | $234M | $183M | · | |
| Receivables | $15M | $16M | $10M | $5M | $267.0K | $6M | $418.0K | $30.0K | $679.0K | $88.0K | |
| Prepaid Expense | $2M | $3M | $8M | $7M | $7M | $11M | $6M | $6M | $2M | $2M | |
| Current Assets | $164M | $289M | $341M | $357M | $507M | $419M | $464M | $375M | $332M | $187M | |
| PP&E (Net) | $4M | $14M | $12M | $16M | $17M | $14M | $11M | $40M | $39M | $40M | |
| PP&E (Gross) | $32M | $46M | $38M | $37M | $33M | $25M | $18M | $47M | $44M | $42M | |
| Accum. Depreciation | $28M | $32M | $26M | $22M | $16M | $11M | $7M | $7M | $4M | $2M | |
| Other Non-current Assets | $3M | $5M | $9M | $5M | $7M | $5M | $5M | $5M | $2M | $2M | |
| Total Assets | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Accounts Payable | $3M | $5M | $8M | $10M | $5M | $6M | $6M | $5M | $4M | $5M | |
| Accrued Liabilities | $33M | $46M | $35M | $31M | $20M | $24M | $22M | $13M | $11M | $17M | |
| Current Liabilities | $46M | $77M | $63M | $60M | $47M | $58M | $60M | $36M | $37M | $33M | |
| Capital Leases | $12M | $20M | $24M | $33M | $16M | $19M | $23M | $32M | $33M | $35M | |
| Other Non-current Liabilities | $3M | $3M | $2M | $0 | · | $28M | $1.0K | $293.0K | $317.0K | $396.0K | |
| Total Liabilities | $159M | $207M | $150M | $154M | $124M | $179M | $246M | $184M | $165M | $95M | |
| Long-term Debt | $59M | $57M | $0 | · | · | · | · | · | · | · | |
| Total Debt | $59M | $57M | · | · | · | · | · | · | · | · | |
| Common Stock | $10.0K | $8.0K | $8.0K | $7.0K | $7.0K | $6.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.63B | $-1.47B | $-1.23B | $-1.08B | $-858M | $-665M | $-549M | $-416M | $-306M | $-186M | |
| AOCI | $0 | $268.0K | $198.0K | $-4M | $-493.0K | $-46.0K | $107.0K | $-29.0K | $-76.0K | · | |
| Stockholders' Equity | $27M | $134M | $349M | $361M | $554M | $394M | $262M | $236M | $208M | $135M | |
| Liabilities + Equity | $187M | $342M | $499M | $514M | $677M | $573M | $509M | $420M | $373M | $229M | |
| Shares Outstanding | 97,866,996 | 82,734,696 | 81,767,263 | 68,847,382 | 68,435,257 | 62,563,457 | 54,355,798 | 48,758,951 | 44,507,960 | 35,818,131 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $10M | $21M | $20M | $29M | $43M | $23M | $27M | $27M | $23M | $17M | |
| Restructuring | · | $12M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $-165M | $-210M | $-132M | $-177M | $-164M | $-180M | $-41M | $-46M | $-9M | $-50M | |
| CapEx | $607.0K | $9M | $5M | $4M | $8M | $7M | $6M | $5M | $2M | $3M | |
| Investing Cash Flow | $139M | $162M | $-4M | $114M | $-54M | $-141M | $12M | $-53M | $-184M | $-3M | |
| Stock Issued | $43M | $0 | $117M | $0 | $249M | $204M | $116M | $77M | $154M | $97M | |
| Net Stock Activity | $43M | $0 | $117M | · | $249M | $204M | $116M | $77M | $154M | $97M | |
| Financing Cash Flow | $40M | $56M | $118M | $1M | $282M | $224M | $132M | $87M | $155M | $97M | |
| Net Change in Cash | $14M | $8M | $-18M | $-62M | $64M | $-96M | $103M | $-12M | $-39M | $43M | |
| Free Cash Flow | $-166M | $-219M | $-137M | $-181M | $-172M | $-187M | $-47M | $-50M | $-11M | $-53M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| Net Margin | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | · | · | |
| EBITDA Margin | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | · | · | |
| ROA | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -40.0% | -51.3% | |
| ROE | -688.8% | -153.0% | -43.2% | -56.9% | -33.8% | -27.8% | -56.6% | -47.7% | -70.2% | -377.5% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 | 7.2 | 7.7 | 10.4 | 9.1 | 5.7 | |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 | 7.0 | 7.6 | 10.3 | 9.0 | 5.6 | |
| Debt / Equity | 2.1 | 0.4 | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 2.0 | 0.4 | · | · | · | · | · | · | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.1 | · | · | |
| Receivables Turnover | 2.6 | 2.4 | 10.2 | 7.3 | 8.1 | 28.1 | 91.7 | 90.1 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.28 | $1.62 | $4.27 | $5.24 | $8.09 | $6.29 | $4.83 | $4.84 | $4.68 | $3.76 | |
| Revenue / Share | $0.46 | $0.39 | $1.03 | $0.29 | $0.38 | · | · | · | · | · | |
| Cash Flow / Share | $-1.86 | $-2.55 | $-1.74 | $-2.58 | $-2.42 | · | · | · | · | · | |
| Cash / Share | $1.50 | $1.59 | $1.51 | $2.06 | $2.97 | $2.23 | $4.38 | $2.76 | $3.29 | $5.17 | |
| EPS (TTM) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 25.4% | -58.6% | 296.3% | -22.8% | -71.9% | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.2% | 8.2% | -4.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -14.9% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $32M | $78M | $20M | $26M | $91M | $21M | $32M | $14M | $6M | |
| Net Income TTM | $-160M | $-237M | $-153M | $-220M | $-193M | $-116M | $-134M | $-110M | $-120M | $-97M | |
| Market Cap | $201M | $105M | $828M | $611M | $1.82B | $4.39B | $1.61B | $1.11B | $1.37B | $581M | |
| Enterprise Value | $113M | $-107M | · | · | · | · | · | · | · | · | |
| P/E | -1.1 | -0.4 | -5.0 | -2.8 | -9.3 | -35.4 | -11.0 | · | · | · | |
| P/S | 5.0 | 3.3 | 10.6 | 31.0 | 71.1 | 48.3 | 78.4 | 34.7 | 99.6 | 96.0 | |
| P/B | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | 6.1 | 4.7 | 6.6 | 4.3 | |
| P / Tangible Book | 7.4 | 0.8 | 2.4 | 1.7 | 3.3 | 11.1 | · | · | · | · | |
| P / Cash Flow | -1.2 | -0.5 | -6.3 | -3.4 | -11.1 | -24.4 | -39.6 | -24.3 | -145.2 | -11.6 | |
| P / FCF | -1.2 | -0.5 | -6.1 | -3.4 | -10.6 | -23.5 | -34.4 | -22.0 | -119.2 | -10.9 | |
| EV / EBITDA | -0.7 | 0.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | -0.7 | 0.5 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 2.8 | -3.3 | · | · | · | · | · | · | · | · | |
| Earnings Yield | -87.8% | -226.8% | -19.9% | -36.2% | -10.7% | -2.8% | -9.0% | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12M | $3M | $25M | $8M | $4M | $5M | $31M | $61.0K | $513.0K | $1M | $60M | $5M | $3M | $10M | $42.0K | $6M | |
| R&D Expense | $20M | $18M | $27M | $20M | $16M | $27M | $49M | $48M | $54M | $49M | $70M | $41M | $30M | $38M | $41M | $44M | |
| SG&A Expense | $12M | $10M | $11M | $12M | $13M | $13M | $16M | $18M | $18M | $19M | $14M | $15M | $17M | $23M | $16M | $17M | |
| Operating Expenses | $30M | $28M | $32M | $32M | $55M | $81M | $77M | $66M | $72M | $68M | $84M | $55M | $47M | $61M | $58M | $61M | |
| Operating Income | $-19M | $-25M | $-8M | $-25M | $-52M | $-76M | $-47M | $-66M | $-72M | $-67M | $-24M | $-50M | $-44M | $-51M | $-58M | $-54M | |
| Other Non-op | $17.0K | $-113.0K | $-5.0K | $-1.0K | $-2M | $-425.0K | $-3.0K | $-5.0K | $-1.0K | $6.0K | $-13.0K | $0 | $-7.0K | $-2M | $1.0K | $235.0K | |
| Net Income | $-18M | $-25M | $-6M | $-25M | $-53M | $-76M | $-45M | $-62M | $-68M | $-62M | $-19M | $-45M | $-40M | $-49M | $-56M | $-53M | |
| EPS (Basic) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| EPS (Diluted) | $-0.15 | $-0.26 | $0.03 | $-0.28 | $-0.63 | $-0.92 | $-0.55 | $-0.75 | $-0.82 | $-0.76 | $-0.20 | $-0.55 | $-0.56 | $-0.71 | $-0.81 | $-0.78 | |
| Shares (Basic) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| Shares (Diluted) | 119,294,615 | 97,879,343 | · | 90,090,397 | 84,412,200 | 83,055,066 | · | 82,485,199 | 82,310,368 | 81,938,839 | · | 81,648,250 | 71,376,678 | 68,924,180 | 68,736,125 | 68,640,858 | |
| EBITDA | $-19M | $-25M | · | $-25M | $-52M | $-76M | · | $-66M | $-72M | $-67M | · | $-50M | $-44M | $-51M | $-58M | $-54M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $124M | $147M | $166M | $139M | $139M | $132M | $96M | $64M | $69M | $124M | $83M | $221M | $129M | $211M | $169M | |
| Short-term Investments | $30M | · | $0 | $0 | $40M | $82M | $138M | $169M | $215M | $227M | $199M | $267M | $211M | $189M | $209M | $283M | |
| Receivables | $3M | $3M | $15M | $8M | $588.0K | $510.0K | $16M | $126.0K | $244.0K | $245.0K | $10M | $2M | $2M | $242.0K | $120.0K | $713.0K | |
| Prepaid Expense | $4M | $2M | $2M | $3M | $4M | $3M | $3M | $6M | $7M | $9M | $8M | $7M | $7M | $6M | $7M | $8M | |
| Current Assets | $218M | $128M | $164M | $177M | $183M | $225M | $289M | $271M | $286M | $306M | $341M | $359M | $441M | $324M | $427M | $461M | |
| PP&E (Net) | $3M | $3M | $4M | $4M | $5M | $8M | $14M | $15M | $14M | $13M | $12M | $12M | $13M | $13M | $15M | $16M | |
| PP&E (Gross) | $29M | $29M | $32M | $32M | $31M | $36M | $46M | $46M | $43M | $41M | $38M | $37M | $36M | $35M | $36M | $35M | |
| Accum. Depreciation | $27M | $26M | $28M | $28M | $27M | $28M | $32M | $31M | $29M | $28M | $26M | $25M | $23M | $22M | $20M | $19M | |
| Other Non-current Assets | $3M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $8M | $9M | $9M | $6M | $5M | $7M | $8M | $8M | |
| Total Assets | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Accounts Payable | $5M | $4M | $3M | $3M | $7M | $5M | $5M | $12M | $14M | $8M | $8M | $10M | $8M | $9M | $7M | $6M | |
| Accrued Liabilities | $17M | $21M | $33M | $48M | $48M | $47M | $46M | $29M | $28M | $31M | $35M | $30M | $28M | $32M | $19M | $20M | |
| Current Liabilities | $68M | $40M | $46M | $62M | $66M | $73M | $77M | $72M | $74M | $66M | $63M | $59M | $55M | $57M | $42M | $36M | |
| Capital Leases | $9M | $11M | $12M | $14M | $15M | $18M | $20M | $22M | $21M | $22M | $24M | $25M | $27M | $29M | $9M | $10M | |
| Other Non-current Liabilities | $2M | $3M | $3M | $5M | $5M | $6M | $3M | $3M | $4M | $3M | $2M | · | · | · | · | · | |
| Total Liabilities | $132M | $145M | $159M | $188M | $191M | $201M | $207M | $152M | $153M | $146M | $150M | $144M | $142M | $147M | $116M | $115M | |
| Long-term Debt | $56M | $55M | $59M | $59M | $57M | $55M | $57M | · | · | · | $0 | · | · | · | · | · | |
| Total Debt | $56M | $55M | · | $59M | $57M | $55M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $15.0K | $10.0K | $10.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | |
| Retained Earnings | $-1.67B | $-1.65B | $-1.63B | $-1.62B | $-1.60B | $-1.54B | $-1.47B | $-1.42B | $-1.36B | $-1.29B | $-1.23B | $-1.21B | $-1.17B | $-1.13B | $-1.02B | $-962M | |
| AOCI | $-6.0K | $0 | $0 | $0 | $15.0K | $88.0K | $268.0K | $522.0K | $-442.0K | $-326.0K | $198.0K | $-1M | $-2M | $-2M | $-4M | $-3M | |
| Stockholders' Equity | $105M | $4M | $27M | $13M | $19M | $62M | $134M | $176M | $232M | $294M | $349M | $360M | $400M | $317M | $415M | $465M | |
| Liabilities + Equity | $237M | $149M | $187M | $202M | $211M | $264M | $342M | $328M | $385M | $440M | $499M | $505M | $542M | $464M | $531M | $581M | |
| Shares Outstanding | 97,866,996 | 97,866,996 | 97,866,996 | 93,264,421 | 87,388,425 | 83,709,536 | 82,734,696 | 82,538,624 | 82,429,514 | 82,234,951 | 81,767,263 | 81,668,796 | 81,616,909 | 68,993,591 | 68,761,729 | 68,718,434 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $2M | $2M | $3M | $3M | $4M | $5M | $5M | $8M | $5M | $5M | $5M | $5M | $6M | $7M | |
| Restructuring | · | · | · | · | · | $53M | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-30M | $-23M | $-36M | $-31M | $-50M | $-48M | $-51M | $-53M | $-57M | $-50M | $-22M | $-35M | $-39M | $-36M | $-48M | $-38M | |
| CapEx | $106.0K | $92.0K | $60.0K | $433.0K | $0 | $114.0K | $540.0K | $3M | $3M | $2M | $1M | $239.0K | $1M | $2M | $614.0K | $632.0K | |
| Investing Cash Flow | $-30M | $64.0K | $58.0K | $40M | $43M | $56M | $31M | $84M | $52M | $-5M | $63M | $-103M | $13M | $23M | $89M | $-4M | |
| Stock Issued | $117M | $0 | $17M | $17M | $7M | $1M | $0 | $0 | $0 | $0 | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | $0 | · | · | · | $1M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $118M | $0 | $17M | $17M | $7M | $-1M | $56M | $0 | $322.0K | $192.0K | $514.0K | $0 | $118M | $0 | $80.0K | $367.0K | |
| Net Change in Cash | $58M | $-23M | $-19M | $26M | $-150.0K | $7M | $36M | $31M | $-5M | $-54M | $41M | $-138M | $92M | $-13M | $41M | $-41M | |
| Free Cash Flow | · | $-23M | · | · | · | $-48M | · | · | · | $-52M | · | · | · | $-38M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| Net Margin | -153.3% | -882.4% | · | -333.0% | -1487.8% | -1633.5% | · | -101870.5% | -13178.8% | -5458.1% | · | -843.7% | -1395.6% | -497.8% | -132681.0% | -840.2% | |
| EBITDA Margin | -156.1% | -883.2% | · | -325.4% | -1440.6% | -1635.1% | · | -107649.2% | -14016.2% | -5902.3% | · | -940.1% | -1527.3% | -517.3% | -136952.4% | -852.5% | |
| ROA | -8.1% | -12.1% | · | -9.5% | -17.9% | -21.6% | · | -14.9% | -14.6% | -13.7% | · | -8.7% | -7.2% | -9.0% | -8.9% | -8.0% | |
| ROE | -29.3% | -74.8% | · | -26.6% | -42.4% | -42.6% | · | -23.2% | -21.4% | -20.2% | · | -11.6% | -9.3% | -11.8% | -11.1% | -9.9% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | 3.2 | · | 2.9 | 2.8 | 3.1 | · | 3.7 | 3.9 | 4.6 | · | 6.1 | 8.1 | 5.7 | 10.1 | 12.7 | |
| Quick Ratio | 3.1 | 3.2 | · | 2.8 | 2.7 | 3.0 | · | 3.7 | 3.8 | 4.5 | · | 6.0 | 8.0 | 5.6 | 9.9 | 12.4 | |
| Debt / Equity | 0.5 | 12.4 | · | 4.4 | 3.0 | 0.9 | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 10.7 | · | 4.0 | 2.7 | 0.8 | · | · | · | · | · | · | · | · | · | · |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 7.2 | 1.8 | · | 1.8 | 8.6 | 12.3 | · | 0.0 | 0.4 | 4.7 | · | 4.2 | 1.9 | 12.2 | 0.2 | 12.2 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.08 | $0.04 | · | $0.14 | $0.22 | $0.75 | · | $2.13 | $2.81 | $3.58 | · | $4.41 | $4.90 | $4.60 | $6.03 | $6.77 | |
| Revenue / Share | $0.10 | $0.03 | · | $0.08 | $0.04 | $0.06 | · | $0.00 | $0.01 | $0.01 | · | $0.07 | $0.04 | $0.14 | $0.00 | $0.09 | |
| Cash Flow / Share | · | $-0.24 | · | · | · | $-0.58 | · | · | · | $-0.61 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $1.86 | $1.26 | · | $1.78 | $1.59 | $1.66 | · | $1.16 | $0.78 | $0.84 | · | $1.01 | $2.71 | $1.87 | $3.06 | $2.47 | |
| EPS (TTM) | $-0.66 | $-1.14 | · | $-2.38 | $-2.85 | $-3.04 | · | $-2.53 | $-2.33 | $-2.07 | · | $-2.70 | $-2.96 | $-3.18 | $-2.94 | $-2.70 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $47M | $39M | · | $46M | $39M | $36M | · | $62M | $67M | $69M | · | $25M | $19M | $23M | $26M | $32M | |
| Net Income TTM | $-74M | $-109M | · | $-200M | $-237M | $-251M | · | $-211M | $-193M | $-166M | · | $-195M | $-206M | $-219M | $-201M | $-184M | |
| Market Cap | $317M | $242M | · | $324M | $192M | $97M | · | $281M | $385M | $610M | · | $637M | $672M | $500M | $842M | $813M | |
| Enterprise Value | $161M | $173M | · | $217M | $70M | $-69M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -4.9 | -2.2 | · | -1.5 | -0.8 | -0.4 | · | -1.3 | -2.0 | -3.6 | · | -2.9 | -2.8 | -2.3 | -4.2 | -4.4 | |
| P/S | 6.7 | 6.2 | · | 7.0 | 4.9 | 2.7 | · | 4.6 | 5.7 | 8.8 | · | 25.9 | 34.8 | 21.9 | 32.8 | 25.6 | |
| P/B | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Tangible Book | 3.0 | 54.8 | · | 24.1 | 10.0 | 1.6 | · | 1.6 | 1.7 | 2.1 | · | 1.8 | 1.7 | 1.6 | 2.0 | 1.7 | |
| P / Cash Flow | · | -10.5 | · | · | · | -2.0 | · | · | · | -12.2 | · | · | · | -14.0 | · | · | |
| EV / Revenue | 3.4 | 4.5 | · | 4.7 | 1.8 | -1.9 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -20.4% | -46.2% | · | -68.6% | -129.6% | -262.1% | · | -74.2% | -49.9% | -27.9% | · | -34.6% | -36.0% | -43.9% | -24.0% | -22.8% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $41M | $32M | $78M | $20M | $26M |
| Betriebsgewinnmarge % | -394.9% | -777.2% | -216.6% | -1146.3% | -756.1% |
| Nettoergebnis | $-160M | $-237M | $-153M | $-220M | $-193M |
| Verwässerte EPS | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 2.1 | 0.4 | · | · | · |
| Liquiditätsgrad | 3.5 | 3.7 | 5.4 | 5.9 | 10.8 |
| Quick Ratio | 3.5 | 3.7 | 5.3 | 5.8 | 10.7 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-166M | $-219M | $-137M | $-181M | $-172M |
Institutionelle Eigentümer (13F) 236 Einreicher · $406.3M gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
236
Gehaltener Wert
$406.3M
Neue Positionen
38
Geschlossene Positionen
23
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 38 (-7 vs. Vorquartal) | 23 (-3 vs. Vorquartal) | 80 (+22 vs. Vorquartal) | 42 (-8 vs. Vorquartal) | +68.9M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.000.000 | 11.111.111 | 8,86% | Aktien |
| BlackRock, Inc. | $34.311.568 | 10.589.990 | 8,44% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $28.800.360 | 8.889.000 | 7,09% | Aktien |
| Commodore Capital LP | $28.800.360 | 8.889.000 | 7,09% | Aktien |
| ADAR1 Capital Management, LLC | $28.800.360 | 8.889.000 | 7,09% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.897.929 | 6.141.336 | 4,90% | Aktien |
| Paradigm Biocapital Advisors LP | $18.100.665 | 5.586.625 | 4,45% | Aktien |
| VANGUARD GROUP INC | $16.826.539 | 8.208.068 | 4,14% | Aktien |
| Opaleye Management Inc. | $12.512.653 | 3.861.930 | 3,08% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $11.658.618 | 3.598.339 | 2,87% | Aktien |
| Woodline Partners LP | $11.519.810 | 3.555.497 | 2,84% | Aktien |
| Vivo Capital, LLC | $11.519.010 | 3.555.250 | 2,83% | Aktien |
| GordonMD Global Investments LP | $10.131.480 | 3.127.000 | 2,49% | Aktien |
| GOLDMAN SACHS GROUP INC | $8.469.476 | 2.614.036 | 2,08% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $8.325.643 | 2.569.072 | 2,05% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $7.999.298 | 2.468.919 | 1,97% | Aktien |
| Logos Global Management LP | $7.199.280 | 2.222.000 | 1,77% | Aktien |
| STATE STREET CORP | $7.101.442 | 2.191.803 | 1,75% | Aktien |
| MARSHALL WACE, LLP | $6.600.808 | 2.037.287 | 1,62% | Aktien |
| D. E. Shaw & Co., Inc. | $6.159.246 | 1.901.002 | 1,52% | Aktien |
| JPMORGAN CHASE & CO | $5.959.980 | 1.862.494 | 1,47% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $5.094.065 | 1.572.242 | 1,25% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $4.318.842 | 1.332.976 | 1,06% | Aktien |
| Seven Fleet Capital Management LP | $4.310.820 | 1.330.500 | 1,06% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $4.273.389 | 1.318.947 | 1,05% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.344.111 | 1.032.133 | 0,82% | Aktien |
| MACKENZIE FINANCIAL CORP | $2.844.856 | 878.042 | 0,70% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $2.812.424 | 868.032 | 0,69% | Aktien |
| Nantahala Capital Management, LLC | $2.762.748 | 852.700 | 0,68% | Aktien |
| NORTHERN TRUST CORP | $2.655.806 | 819.693 | 0,65% | Aktien |
| TWO SIGMA ADVISERS, LP | $2.509.405 | 1.224.100 | 0,62% | Aktien |
| UBS Group AG | $2.432.472 | 750.763 | 0,60% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $2.407.158 | 742.950 | 0,59% | Aktien |
| Nuveen, LLC | $1.688.730 | 521.213 | 0,42% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $1.616.750 | 498.997 | 0,40% | Aktien |
| Susquehanna Portfolio Strategies, LLC | $1.545.801 | 477.099 | 0,38% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.521.180 | 469.500 | 0,37% | Kaufoption |
| Eversept Partners, LP | $1.486.541 | 458.809 | 0,37% | Aktien |
| Casdin Capital, LLC | $1.441.800 | 445.000 | 0,35% | Aktien |
| PEAK6 LLC | $1.346.029 | 415.441 | 0,33% | Aktien |
| DIADEMA PARTNERS LP | $1.296.000 | 400.000 | 0,32% | Kaufoption |
| MORGAN STANLEY | $1.108.616 | 342.165 | 0,27% | Aktien |
| BIT Capital GmbH | $1.056.240 | 326.000 | 0,26% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $1.002.440 | 309.395 | 0,25% | Aktien |
| Cubist Systematic Strategies, LLC | $994.094 | 286.482 | 0,24% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $878.642 | 271.186 | 0,22% | Aktien |
| Bank of New York Mellon Corp | $850.907 | 262.625 | 0,21% | Aktien |
| BANK OF AMERICA CORP /DE/ | $751.119 | 231.827 | 0,18% | Aktien |
| LPL Financial LLC | $748.813 | 231.115 | 0,18% | Aktien |
| Erste Asset Management GmbH | $736.000 | 230.000 | 0,18% | Aktien |
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Polaris Venture Partners VI, L.P. (“PVP VI”), Polaris Venture Founders’ Fund VI, L.P. (“PVPFF VI”), Polaris Venture Management Co. VI, L.L.C. (“PVM VI”), Jonathan A. Flint (“Flint”), Terrance G. McGuire (“McGuire”), Brian Chee (“Chee”), David Barrett (“Barrett”), Amir Nashat (“Nashat”), Bryce Youngren (“Youngren”) ×4 Einreichungen | 18. September 2017 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 35 Insider · 17 Führungskräfte · 17 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Gilmore Neil O'Neill | CEO | 3. September 2026 S | 243.189 | 0 | 4 | $-80.045 |
| MULLEN JAMES C | CEO | 14. April 2022 A | 75.898 | 0 | 0 | $0 |
| Cynthia Collins | CEO | 9. Februar 2021 S | 43.760 | 0 | 0 | $0 |
| Katrine Bosley | President and CEO | 8. Januar 2019 S | 1.204.966 | 0 | 0 | $0 |
| Amy Parison | SVP, Chief Financial Officer | 3. September 2026 S | 13.839 | 0 | 5 | $-6.327 |
| Erick Lucera | EVP, CHIEF FINANCIAL OFFICER | 8. März 2025 A | 112.720 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 11. Mai 2023 S | 106.610 | 0 | 0 | $0 |
| Andrew A. F. Hack | Chief Financial Officer | 4. Februar 2019 M | 0 | 0 | 0 | $0 |
| Daniel Scott Ory | EVP, Chief Medical Officer | 8. September 2026 A | · | 0 | 0 | $0 |
| Linda Burkly | EVP, CHIEF SCIENTIFIC OFFICER | 3. September 2026 S | 61.660 | 0 | 5 | $-20.333 |
| Baisong Mei | EVP, CHIEF MEDICAL OFFICER | 3. Dezember 2024 S | 133.354 | 0 | 0 | $0 |
| Bruce Eaton | EVP, CBO AND CTO | 5. Dezember 2023 S | 74.791 | 0 | 0 | $0 |
| Mark S Shearman | EVP, CHIEF SCIENTIFIC OFFICER | 13. Februar 2023 S | 65.559 | 0 | 0 | $0 |
| Lisa Anne Michaels | EVP/Chief Medical Officer | 22. Dezember 2021 A | 22.675 | 0 | 0 | $0 |
| Judith R Abrams | Chief Medical Officer | 28. Oktober 2019 A | 25.000 | 0 | 0 | $0 |
| Vickesh Myer | Chief Technology Officer | 18. März 2019 M | 0 | 0 | 0 | $0 |
| Gerald Frank Cox | Chief Medical Officer | 7. Februar 2018 A | 4.000 | 0 | 0 | $0 |
| Patrick Thomas Ellinor II | Direktor | 6. August 2026 A | · | 0 | 0 | $0 |
| Elliott M. Levy | Direktor | 17. Juni 2026 A | · | 0 | 0 | $0 |
| David Scadden | Direktor | 17. Juni 2026 A | · | 0 | 0 | $0 |
| Bernadette Connaughton | Direktor | 17. Juni 2026 A | · | 0 | 0 | $0 |
| Jessica Hopfield | Direktor | 17. Juni 2026 A | 67.700 | 0 | 0 | $0 |
| Andrew Hirsch | Direktor | 17. Juni 2026 A | · | 0 | 0 | $0 |
| Meeta Chatterjee | Direktor | 30. Mai 2024 A | · | 0 | 0 | $0 |
| Emma Reeve | Direktor | 30. Mai 2024 A | · | 0 | 0 | $0 |
| Akshay Vaishnaw | Direktor | 30. Mai 2024 A | · | 0 | 0 | $0 |
| Boris Nikolic | Direktor | 15. Juni 2018 A | 35.000 | 0 | 0 | $0 |
| Douglas G. Cole | Direktor | 17. August 2017 J | 3.171 | 0 | 0 | $0 |
| Kevin Bitterman | Direktor | 15. Juni 2017 A | 2.797.144 | 0 | 0 | $0 |
| Alexis Borisy | Direktor | 15. Juni 2017 A | 0 | 0 | 0 | $0 |
| John Mendlein | Direktor | 15. Juni 2017 A | · | 0 | 0 | $0 |
| Kevin P Starr | 10%-Eigentümer | 6. September 2016 S | 0 | 0 | 0 | $0 |
| bng0, LLC | 10%-Eigentümer | 8. Februar 2016 C | 2.649.572 | 0 | 0 | $0 |
| Charles Albright | · | 15. Dezember 2020 M | 24.907 | 0 | 0 | $0 |
| Alexandra Glucksmann | · | 15. März 2017 M | 117.788 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 17 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 39.171 SH | 2. Oktober 2026 | Täglich |
| IWC · iShares Trust | 0,06% | 339.728 SH | 11. September 2026 | Täglich |
| IBB · iShares Trust | 0,03% | 1.101.092 SH | 11. September 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 11.076 SH | 1. Oktober 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,02% | 96.927 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 170.052 SH | 2. Oktober 2026 | Täglich |
| IWO · iShares Trust | 0,02% | 844.017 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 575.834 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 461.967 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,01% | 2.588.297 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 47.823 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 19.230 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 1.100.306 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.890.144 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 9.046 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.608 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 120.579 SH | 11. September 2026 | Täglich |
EDIT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 18 Analysten
KAUF
Median-Ziel
$5.00
+90,8%
5 27,8%
Starker Kauf
7 38,9%
Kauf
4 22,2%
Halten
2 11,1%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
10 Analysten · 2026-09-27Mittelwert-Ziel $5.90 +125,2%
Jetzt
Aktueller Preis $2.62
Tief$1.00
Mittelwert$5.90
Hoch$15.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | · |
| EIKN | · | · | · | · | · | · |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 5, 2026